Monthly
US$200
Billed every month
Bumetanide Injection(布美他尼注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 1 applicationNo longer listed under review: 4 applicationsNotification delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders39View records ↓
Under-review filings13View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers57View records ↓
API companies with A status24View records ↓
Chemical-drug catalogue
Loaded records: 39 holders; 3 in the quality-and-efficacy consistency-evaluation category, and 35 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 信合援生制药股份有限公司 | 信合援生制药股份有限公司 | 国药准字H20266280 | 2026/10/13 | 4ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中山万汉制药有限公司 | 中山万汉制药有限公司 | 国药准字H20265932 | 2026/09/15 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中山万汉制药有限公司 | 中山万汉制药有限公司 | 国药准字H20265931 | 2026/09/15 | 2ml:1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东诺明康药物研究院有限公司 | 济宁神州医药有限公司 | 国药准字H20265596 | 2026/08/04 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏开元药业有限公司 | 江苏苏中药业集团生物制药有限公司 | 国药准字H20265597 | 2026/08/04 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 酒泉大得利制药股份有限公司 | 酒泉大得利制药股份有限公司 | 国药准字H20265458 | 2026/08/04 | 4ml:1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 酒泉大得利制药股份有限公司 | 酒泉大得利制药股份有限公司 | 国药准字H20265457 | 2026/08/04 | 2ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南华派医药科技有限公司 | 楚雄和创药业有限责任公司 | 国药准字H20265514 | 2026/08/04 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河南欣泰药业有限公司 | 河南欣泰药业有限公司 | 国药准字H20057376 | 2026/07/30 | 2ml:0.5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 山东方明药业集团股份有限公司 | 山东方明药业集团股份有限公司 | 国药准字H20265213 | 2026/07/21 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宁波大红鹰药业股份有限公司 | 宁波大红鹰药业股份有限公司 | 国药准字H33020980 | 2026/06/26 | 2ml:0.5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 江苏迪赛诺制药有限公司 | 江苏迪赛诺制药有限公司 | 国药准字H20264734 | 2026/06/10 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东道齐生物医药科技有限公司 | 成都市海通药业有限公司 | 国药准字H20269129 | 2026/06/02 | 1ml∶0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏润恒制药有限公司 | 江苏润恒制药有限公司 | 国药准字H20264515 | 2026/05/27 | 2ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏润恒制药有限公司 | 江苏润恒制药有限公司 | 国药准字H20264514 | 2026/05/27 | 2ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南慧通生物医药科技有限公司 | 山东北大高科华泰制药有限公司 | 国药准字H20264479 | 2026/05/19 | 1ml ： 0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南慧通生物医药科技有限公司 | 山东北大高科华泰制药有限公司 | 国药准字H20264478 | 2026/05/19 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20264440 | 2026/05/19 | 1ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川美大康华康药业有限公司 | 四川美大康华康药业有限公司 | 国药准字H20269095 | 2026/04/21 | 1ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 辰欣药业股份有限公司 | 辰欣药业股份有限公司 | 国药准字H20263951 | 2026/04/14 | 4ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新华制药股份有限公司 | 山西诺成制药有限公司 | 国药准字H20263885 | 2026/04/07 | 4ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新华制药股份有限公司 | 山西诺成制药有限公司 | 国药准字H20263884 | 2026/04/07 | 2ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 新乡市常乐制药有限责任公司 | 新乡市常乐制药有限责任公司 | 国药准字H20269077 | 2026/03/27 | 1ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20263723 | 2026/03/25 | 2ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川沃翔生物医药有限公司 | 成都第一制药有限公司 | 国药准字H20263469 | 2026/02/25 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州朗科生物技术股份有限公司 | 扬州中宝药业股份有限公司 | 国药准字H20263182 | 2026/01/20 | 2ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州特瑞药业股份有限公司 | 江苏华阳制药有限公司 | 国药准字H20263065 | 2026/01/14 | 4ml : 2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川奇裕医药科技有限公司 | 四川美大康佳乐药业有限公司 | 国药准字H20263061 | 2026/01/14 | 4ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州特瑞药业股份有限公司 | 江苏华阳制药有限公司 | 国药准字H20263066 | 2026/01/14 | 1ml : 0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南卓科制药有限公司 | 海南卓科制药有限公司 | 国药准字H20263011 | 2026/01/05 | 1ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南卓科制药有限公司 | 海南卓科制药有限公司 | 国药准字H20263012 | 2026/01/05 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏宝东医药科技有限公司 | 山东豪瑞恩制药有限公司 | 国药准字H20256301 | 2025/12/16 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏宝东医药科技有限公司 | 山东豪瑞恩制药有限公司 | 国药准字H20256300 | 2025/12/16 | 2ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京六环药业有限公司 | 华夏生生药业（北京）有限公司 | 国药准字H20256311 | 2025/12/16 | 4ml∶2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 国药集团容生制药有限公司 | 国药集团容生制药有限公司 | 国药准字H20256235 | 2025/12/09 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 卡文迪许（泰州）药业有限公司 | 江苏悦兴药业有限公司 | 国药准字H20256032 | 2025/11/25 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华夏生生药业（北京）有限公司 | 华夏生生药业（北京）有限公司 | 国药准字H20256033 | 2025/11/25 | 4ml∶2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 齐鲁制药（海南）有限公司 | 齐鲁制药（海南）有限公司 | 国药准字H20255275 | 2025/09/02 | 4ml: 2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 深圳格莱恩生物医药科技有限公司 | 中山万汉制药有限公司 | 国药准字H20255333 | 2025/09/02 | 4ml:1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中山万汉制药有限公司 | 中山万汉制药有限公司 | 国药准字H20255030 | 2025/07/29 | 4ml:1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都瑞尔医药科技有限公司 | 太极集团四川太极制药有限公司 | 国药准字H20254921 | 2025/07/22 | 2ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都瑞尔医药科技有限公司 | 太极集团四川太极制药有限公司 | 国药准字H20254920 | 2025/07/22 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都米子生物医药科技有限公司 | 成都天台山制药股份有限公司 | 国药准字H20254456 | 2025/06/03 | 2ml∶0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东道齐生物医药科技有限公司 | 成都市海通药业有限公司 | 国药准字H20254036 | 2025/04/30 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川美大康华康药业有限公司 | 四川美大康华康药业有限公司 | 国药准字H20253699 | 2025/03/25 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都苑东生物制药股份有限公司 | 成都苑东生物制药股份有限公司 | 国药准字H20253233 | 2025/01/24 | 4ml:1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 新乡市常乐制药有限责任公司 | 新乡市常乐制药有限责任公司 | 国药准字H20249747 | 2024/12/17 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州沐源生物医药科技有限公司 | 成都市海通药业有限公司 | 国药准字H20249728 | 2024/12/10 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都欣捷高新技术开发股份有限公司 | 峨眉山通惠制药有限公司 | 国药准字H20244549 | 2024/07/30 | 4ml:1mg | Not stated by source | CDE |
| 桂林南药股份有限公司 | 桂林南药股份有限公司 | 国药准字H20057225 | 2024/04/15 | 2ml:1mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 桂林南药股份有限公司 | 桂林南药股份有限公司 | 国药准字H20247066 | 2024/04/15 | 1ml:0.5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 平光制药股份有限公司 | 平光制药股份有限公司 | 国药准字H20264124 | 2026/04/21 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏迪赛诺制药有限公司 | 江苏迪赛诺制药有限公司 | 国药准字H20264735 | 2026/06/10 | 2ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都康泰源医药科技有限责任公司 | 湖南科伦制药有限公司 | 国药准字H20266291 | 2026/10/20 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东健信制药股份有限公司 | 中山万汉制药有限公司 | 国药准字H20264569 | 2026/05/27 | 4ml:1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 57 distinct approval numbers and 45 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京市永康药业有限公司 | 国药准字H11020587 | 2ml：0.5mg | Category B (乙) | XC03CAB176B002010100137 | NHSA |
| 广东邦民制药厂有限公司 | 国药准字H20066846 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010100267 | NHSA |
| 上海禾丰制药有限公司 | 国药准字H31021523 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010100673 | NHSA |
| 西南药业股份有限公司 | 国药准字H50021461 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010100978 | NHSA |
| 辽宁玉皇药业有限公司 | 国药准字H20083500 | 2ml:1mg | Category B (乙) | XC03CAB176B002010101247 | NHSA |
| 江苏迪赛诺制药有限公司 | 国药准字H20264734 | 4ml:2mg | Category B (乙) | XC03CAB176B002010101495 | NHSA |
| 湖北津药药业股份有限公司 | 国药准字H20057023 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010101866 | NHSA |
| 武汉久安药业有限公司 | 国药准字H42020894 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010101949 | NHSA |
| 四川沃翔生物医药有限公司 | 国药准字H20263469 | 4ml:2mg | Category B (乙) | XC03CAB176B002010102065 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H20253699 | 4ml:2mg | Category B (乙) | XC03CAB176B002010102087 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20253233 | 4ml:1mg | Category B (乙) | XC03CAB176B002010102181 | NHSA |
| 石家庄四药有限公司 | 国药准字H20263723 | 2ml:1mg | Category B (乙) | XC03CAB176B002010102763 | NHSA |
| 河南欣泰药业有限公司 | 国药准字H20057376 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010103091 | NHSA |
| 国药集团容生制药有限公司 | 国药准字H20256235 | 4ml:2mg | Category B (乙) | XC03CAB176B002010103205 | NHSA |
| 新乡市常乐制药有限责任公司 | 国药准字H20249747 | 4ml: 2mg | Category B (乙) | XC03CAB176B002010103216 | NHSA |
| 山东方明药业集团股份有限公司 | 国药准字H20265213 | 4ml:2mg | Category B (乙) | XC03CAB176B002010104083 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20263951 | 4ml:1mg | Category B (乙) | XC03CAB176B002010104127 | NHSA |
| 宁波大红鹰药业股份有限公司 | 国药准字H33020980 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010104757 | NHSA |
| 福州海王福药制药有限公司 | 国药准字H35020460 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010104827 | NHSA |
| 广西梧州制药(集团)股份有限公司 | 国药准字H45020076 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010105156 | NHSA |
| 桂林南药股份有限公司 | 国药准字H45020960 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010105206 | NHSA |
| 海南久常制药有限公司 | 国药准字H20057248 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010105843 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20255275 | 4ml: 2mg | Category B (乙) | XC03CAB176B002010105847 | NHSA |
| 甘肃成纪生物药业有限公司 | 国药准字H20163098 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010107698 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20256033 | 4ml∶2mg | Category B (乙) | XC03CAB176B002010109910 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20255030 | 4ml:1mg | Category B (乙) | XC03CAB176B002010109920 | NHSA |
| 广东健信制药股份有限公司 | 国药准字H20264569 | 4ml:1mg | Category B (乙) | XC03CAB176B002010109921 | NHSA |
| 苏州特瑞药业股份有限公司 | 国药准字H20263065 | 4ml : 2mg | Category B (乙) | XC03CAB176B002010110121 | NHSA |
| 平光制药股份有限公司 | 国药准字H20264124 | 4ml:2mg | Category B (乙) | XC03CAB176B002010180610 | NHSA |
| 海南卓科制药有限公司 | 国药准字H20263011 | 1ml:0.5mg | Category B (乙) | XC03CAB176B002010182234 | NHSA |
| 山东致泰医药技术有限公司 | 国药准字H20264071 | 4ml : 2mg | Category B (乙) | XC03CAB176B002010183094 | NHSA |
| 成都欣捷高新技术开发股份有限公司 | 国药准字H20244549 | 4ml∶1mg | Category B (乙) | XC03CAB176B002010183325 | NHSA |
| 苏州朗科生物技术股份有限公司 | 国药准字H20263182 | 2ml:1mg | Category B (乙) | XC03CAB176B002010183485 | NHSA |
| 山东道齐生物医药科技有限公司 | 国药准字H20254036 | 4ml:2mg | Category B (乙) | XC03CAB176B002010183960 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20249728 | 4ml:2mg | Category B (乙) | XC03CAB176B002010184135 | NHSA |
| 四川奇裕医药科技有限公司 | 国药准字H20263061 | 4ml : 1mg | Category B (乙) | XC03CAB176B002010184156 | NHSA |
| 吉林敖东药业集团延吉股份有限公司 | 国药准字H20254921 | 2ml:1mg | Category B (乙) | XC03CAB176B002010184534 | NHSA |
| 成都利尔药业有限公司 | 国药准字H20256036 | 4ml:2mg | Category B (乙) | XC03CAB176B002010184779 | NHSA |
| 海南慧通生物医药科技有限公司 | 国药准字H20264478 | 4ml:2mg | Category B (乙) | XC03CAB176B002010184954 | NHSA |
| 深圳格莱恩生物医药科技有限公司 | 国药准字H20255333 | 4ml:1mg | Category B (乙) | XC03CAB176B002010185074 | NHSA |
| 江苏润恒制药有限公司 | 国药准字H20264515 | 2ml:1mg | Category B (乙) | XC03CAB176B002010185467 | NHSA |
| 江苏宝东医药科技有限公司 | 国药准字H20256300 | 2ml:1mg | Category B (乙) | XC03CAB176B002010185482 | NHSA |
| 北京六环药业有限公司 | 国药准字H20256311 | 4ml:2mg | Category B (乙) | XC03CAB176B002010185484 | NHSA |
| 江苏润恒制药有限公司 | 国药准字H20264514 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010185560 | NHSA |
| 西南药业股份有限公司 | 国药准字H50021461 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010200978 | NHSA |
| 江苏迪赛诺制药有限公司 | 国药准字H20264734 | 4ml:2mg | Category B (乙) | XC03CAB176B002010201495 | NHSA |
| 湖北津药药业股份有限公司 | 国药准字H20057023 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010201866 | NHSA |
| 武汉久安药业有限公司 | 国药准字H42020894 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010201949 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H20253699 | 4ml:2mg | Category B (乙) | XC03CAB176B002010202087 | NHSA |
| 石家庄四药有限公司 | 国药准字H20263723 | 2ml:1mg | Category B (乙) | XC03CAB176B002010202763 | NHSA |
| 河南欣泰药业有限公司 | 国药准字H20057376 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010203091 | NHSA |
| 国药集团容生制药有限公司 | 国药准字H20256235 | 4ml:2mg | Category B (乙) | XC03CAB176B002010203205 | NHSA |
| 新乡市常乐制药有限责任公司 | 国药准字H20249747 | 4ml: 2mg | Category B (乙) | XC03CAB176B002010203216 | NHSA |
| 山东方明药业集团股份有限公司 | 国药准字H20265213 | 4ml:2mg | Category B (乙) | XC03CAB176B002010204083 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20263951 | 4ml:1mg | Category B (乙) | XC03CAB176B002010204127 | NHSA |
| 广西梧州制药(集团)股份有限公司 | 国药准字H45020076 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010205156 | NHSA |
| 桂林南药股份有限公司 | 国药准字H45020960 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010205206 | NHSA |
| 海南久常制药有限公司 | 国药准字H20057248 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010205843 | NHSA |
| 甘肃成纪生物药业有限公司 | 国药准字H20163098 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010207698 | NHSA |
| 广东健信制药股份有限公司 | 国药准字H20264569 | 4ml:1mg | Category B (乙) | XC03CAB176B002010209921 | NHSA |
| 海南卓科制药有限公司 | 国药准字H20263011 | 1ml:0.5mg | Category B (乙) | XC03CAB176B002010282234 | NHSA |
| 山东致泰医药技术有限公司 | 国药准字H20264071 | 4ml : 2mg | Category B (乙) | XC03CAB176B002010283094 | NHSA |
| 山东道齐生物医药科技有限公司 | 国药准字H20254036 | 4ml:2mg | Category B (乙) | XC03CAB176B002010283960 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20249728 | 4ml:2mg | Category B (乙) | XC03CAB176B002010284135 | NHSA |
| 吉林敖东药业集团延吉股份有限公司 | 国药准字H20254921 | 2ml:1mg | Category B (乙) | XC03CAB176B002010284534 | NHSA |
| 成都利尔药业有限公司 | 国药准字H20256036 | 4ml:2mg | Category B (乙) | XC03CAB176B002010284779 | NHSA |
| 深圳格莱恩生物医药科技有限公司 | 国药准字H20255333 | 4ml:1mg | Category B (乙) | XC03CAB176B002010285074 | NHSA |
| 成都米子生物医药科技有限公司 | 国药准字H20254456 | 2ml∶0.5mg | Category B (乙) | XC03CAB176B002010285135 | NHSA |
| 卡文迪许(泰州)药业有限公司 | 国药准字H20256032 | 4ml:2mg | Category B (乙) | XC03CAB176B002010285170 | NHSA |
| 江苏润恒制药有限公司 | 国药准字H20264515 | 2ml:1mg | Category B (乙) | XC03CAB176B002010285467 | NHSA |
| 江苏宝东医药科技有限公司 | 国药准字H20256300 | 2ml:1mg | Category B (乙) | XC03CAB176B002010285482 | NHSA |
| 江苏润恒制药有限公司 | 国药准字H20264514 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010285560 | NHSA |
| 西南药业股份有限公司 | 国药准字H50021461 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010300978 | NHSA |
| 石家庄四药有限公司 | 国药准字H20263723 | 2ml:1mg | Category B (乙) | XC03CAB176B002010302763 | NHSA |
| 山东方明药业集团股份有限公司 | 国药准字H20265213 | 4ml:2mg | Category B (乙) | XC03CAB176B002010304083 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20263951 | 4ml:1mg | Category B (乙) | XC03CAB176B002010304127 | NHSA |
| 甘肃成纪生物药业有限公司 | 国药准字H20163098 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002010307698 | NHSA |
| 深圳格莱恩生物医药科技有限公司 | 国药准字H20255333 | 4ml:1mg | Category B (乙) | XC03CAB176B002010385074 | NHSA |
| 山东方明药业集团股份有限公司 | 国药准字H20265213 | 4ml:2mg | Category B (乙) | XC03CAB176B002010404083 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20263951 | 4ml:1mg | Category B (乙) | XC03CAB176B002010404127 | NHSA |
| 辽宁玉皇药业有限公司 | 国药准字H20083499 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002020101247 | NHSA |
| 江苏迪赛诺制药有限公司 | 国药准字H20264735 | 2ml:1mg | Category B (乙) | XC03CAB176B002020101495 | NHSA |
| 湖北津药药业股份有限公司 | 国药准字H20057023 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002020101866 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H20269095 | 1ml:0.5mg | Category B (乙) | XC03CAB176B002020102087 | NHSA |
| 石家庄四药有限公司 | 国药准字H20264440 | 1ml:0.5mg | Category B (乙) | XC03CAB176B002020102763 | NHSA |
| 新乡市常乐制药有限责任公司 | 国药准字H20269077 | 1ml:0.5mg | Category B (乙) | XC03CAB176B002020103216 | NHSA |
| 福州海王福药制药有限公司 | 国药准字H35020460 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002020104827 | NHSA |
| 桂林南药股份有限公司 | 国药准字H20057225 | 2ml:1mg | Category B (乙) | XC03CAB176B002020105206 | NHSA |
| 苏州特瑞药业股份有限公司 | 国药准字H20263066 | 1ml : 0.5mg | Category B (乙) | XC03CAB176B002020110121 | NHSA |
| 山东道齐生物医药科技有限公司 | 国药准字H20269129 | 1ml:0.5mg | Category B (乙) | XC03CAB176B002020183960 | NHSA |
| 吉林敖东药业集团延吉股份有限公司 | 国药准字H20254920 | 4ml:2mg | Category B (乙) | XC03CAB176B002020184534 | NHSA |
| 海南慧通生物医药科技有限公司 | 国药准字H20264479 | 1ml:0.5mg | Category B (乙) | XC03CAB176B002020184954 | NHSA |
| 江苏宝东医药科技有限公司 | 国药准字H20256301 | 4ml:2mg | Category B (乙) | XC03CAB176B002020185482 | NHSA |
| 江苏迪赛诺制药有限公司 | 国药准字H20264735 | 2ml:1mg | Category B (乙) | XC03CAB176B002020201495 | NHSA |
| 石家庄四药有限公司 | 国药准字H20264440 | 1ml:0.5mg | Category B (乙) | XC03CAB176B002020202763 | NHSA |
| 山东道齐生物医药科技有限公司 | 国药准字H20269129 | 1ml:0.5mg | Category B (乙) | XC03CAB176B002020283960 | NHSA |
| 吉林敖东药业集团延吉股份有限公司 | 国药准字H20254920 | 4ml:2mg | Category B (乙) | XC03CAB176B002020284534 | NHSA |
| 江苏宝东医药科技有限公司 | 国药准字H20256301 | 4ml:2mg | Category B (乙) | XC03CAB176B002020285482 | NHSA |
| 江苏迪赛诺制药有限公司 | 国药准字H20264735 | 2ml:1mg | Category B (乙) | XC03CAB176B002020301495 | NHSA |
| 湖北津药药业股份有限公司 | 国药准字H20057023 | 2ml:0.5mg | Category B (乙) | XC03CAB176B002020301866 | NHSA |
| 石家庄四药有限公司 | 国药准字H20264440 | 1ml:0.5mg | Category B (乙) | XC03CAB176B002020302763 | NHSA |
| 桂林南药股份有限公司 | 国药准字H20057225 | 2ml:1mg | Category B (乙) | XC03CAB176B002020305206 | NHSA |
| 江苏迪赛诺制药有限公司 | 国药准字H20264735 | 2ml:1mg | Category B (乙) | XC03CAB176B002020401495 | NHSA |
| 桂林南药股份有限公司 | 国药准字H20057225 | 2ml:1mg | Category B (乙) | XC03CAB176B002020405206 | NHSA |
| 卡文迪许(泰州)药业有限公司 | 国药准字H20256032 | 4ml:2mg | Category B (乙) | XC03CAB176B002010385170 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 13 filings and 9 distinct first applicants.
Generic 11 · Supplement 2
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏福邦药业有限公司 | CYHS2600530 | Generic | 2026/02/26 | Not stated by source | CDE |
| 江苏福邦药业有限公司 | CYHS2600529 | Generic | 2026/02/26 | Not stated by source | CDE |
| 丹东医创药业有限责任公司 | CYHS2601384 | Generic | 2026/06/11 | Not stated by source | CDE |
| 丹东医创药业有限责任公司 | CYHS2601382 | Generic | 2026/06/11 | Not stated by source | CDE |
| 武汉海特生物制药股份有限公司 | CYHB2601065 | Supplement | 2026/06/05 | Not stated by source | CDE |
| 马鞍山丰原制药有限公司 | CYHS2601212 | Generic | 2026/05/29 | Not stated by source | CDE |
| 福州海王福药制药有限公司 | CYHB2650108 | Supplement | 2026/04/30 | Not stated by source | CDE |
| 山东益健药业有限公司 | CYHS2503579 | Generic | 2025/09/30 | Not stated by source | CDE |
| 山东益健药业有限公司 | CYHS2503578 | Generic | 2025/09/30 | Not stated by source | CDE |
| 海南普利制药股份有限公司 | CYHS2502591 | Generic | 2025/07/18 | Not stated by source | CDE |
| 山东辉成药业有限公司 | CYHS2501471 | Generic | 2025/04/17 | Not stated by source | CDE |
| 重庆博腾药业有限公司 | CYHS2501196 | Generic | 2025/03/27 | Not stated by source | CDE |
| 武汉海特生物制药股份有限公司 | CYHS2403001 | Generic | 2024/09/11 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 5 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏福邦药业有限公司 | CYHS2600530 | Generic | 2026/02/26 | Not stated by source | CDE |
| 江苏福邦药业有限公司 | CYHS2600529 | Generic | 2026/02/26 | Not stated by source | CDE |
| 丹东医创药业有限责任公司 | CYHS2601384 | Generic | 2026/06/11 | Not stated by source | CDE |
| 丹东医创药业有限责任公司 | CYHS2601382 | Generic | 2026/06/11 | Not stated by source | CDE |
| 马鞍山丰原制药有限公司 | CYHS2601212 | Generic | 2026/05/29 | Not stated by source | CDE |
API registrations
Non-component matches: 24 companies with A status and 3 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 布美他尼 | 宜昌天睿生物医药有限责任公司 | Y20260000184 | I | Exact ingredient | 2026/04/23 | CDE |
| 布美他尼 | 浙江赛默制药有限公司 | Y20240000927 | A | Exact ingredient | 2026/07/13 | CDE |
| 布美他尼 | 绪必迪药业（沧州）有限公司 | Y20240001294 | A | Exact ingredient | 2026/05/07 | CDE |
| 布美他尼 | 河北国龙制药有限公司 | Y20240001211 | A | Exact ingredient | 2026/07/15 | CDE |
| 布美他尼 | 海南普利制药股份有限公司 | Y20240001076 | A | Exact ingredient | 2026/04/01 | CDE |
| 布美他尼 | 山东方明药业集团股份有限公司 | Y20240000859 | A | Exact ingredient | 2026/04/21 | CDE |
| 布美他尼 | 酒泉大得利制药股份有限公司 | Y20240000936 | A | Exact ingredient | 2026/07/01 | CDE |
| 布美他尼 | 杭州澳赛诺生物科技有限公司 | Y20240000761 | A | Exact ingredient | 2026/03/17 | CDE |
| 布美他尼 | 福建南方制药股份有限公司 | Y20240000807 | A | Exact ingredient | 2026/01/08 | CDE |
| 布美他尼 | 山东辰龙药业有限公司 | Y20240000775 | A | Exact ingredient | 2026/06/23 | CDE |
| 布美他尼 | 福建南方制药股份有限公司 | Y20240000623 | I | Exact ingredient | 2024/08/05 | CDE |
| 布美他尼 | 苏州立新制药有限公司 | Y20240000515 | A | Exact ingredient | 2025/11/26 | CDE |
| 布美他尼 | OLON S.P.A. | Y20240000359 | A | Exact ingredient | 2025/12/05 | CDE |
| 布美他尼 | 浙江皓华制药有限公司 | Y20240000188 | A | Exact ingredient | 2025/05/28 | CDE |
| 布美他尼 | 安徽恒星制药有限公司 | Y20230001167 | A | Exact ingredient | 2025/07/01 | CDE |
| 布美他尼 | 海南卓科制药有限公司 | Y20230001090 | A | Exact ingredient | 2025/07/18 | CDE |
| 布美他尼 | INDUSTRIALE CHIMICA S.R.L. | Y20230000563 | A | Exact ingredient | 2026/09/13 | CDE |
| 布美他尼 | 江苏云阳集团药业有限公司 | Y20230000614 | A | Exact ingredient | 2024/11/07 | CDE |
| 布美他尼 | 四川青木制药有限公司 | Y20230000354 | A | Exact ingredient | 2026/03/03 | CDE |
| 布美他尼 | 宿州亿帆药业有限公司 | Y20230000386 | A | Exact ingredient | 2025/06/07 | CDE |
| 布美他尼 | 中山万汉制药有限公司 | Y20230000272 | A | Exact ingredient | 2026/08/15 | CDE |
| 布美他尼 | 成都新恒创药业有限公司 | Y20220001296 | A | Exact ingredient | 2026/01/22 | CDE |
| 布美他尼 | Solara Active Pharma Sciences Limited | Y20210001128 | I | Exact ingredient | 2022/02/23 | CDE |
| 布美他尼 | 丹东医创药业有限责任公司 | Y20190007367 | A | Exact ingredient | — | CDE |
| 布美他尼 | 桂林南药股份有限公司 | Y20190004090 | A | Exact ingredient | 2025/01/18 | CDE |
| 布美他尼 | 海南吾仁制药有限公司 | Y20190002887 | A | Exact ingredient | 2024/09/05 | CDE |
| 布美他尼 | 宁波大红鹰药业股份有限公司 | Y20190002459 | A | Exact ingredient | 2025/01/03 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/09Notification delivery
江苏铭远药业有限公司
CYHS2502623
Fact date: 2026/11/09 (Publication date) · Publication date: 2026/11/09 · Site observation date: 2026/11/09
Notification delivered; the specific outcome remains to be checked.
View source · Table row 4 ↗ -
2026/11/07No longer listed under review
合肥源丰顺医药科技有限公司;成都百裕制药股份有限公司
CYHS2501389
Fact date: 2026/11/07 · Site observation date: 2026/11/07
Accepted: 2025/04/10
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/11/06No longer listed under review
江西人可医药科技有限公司;裕松源药业有限公司
CYHS2500702
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2025/02/12
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/11/06No longer listed under review
江西人可医药科技有限公司;裕松源药业有限公司
CYHS2500701
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2025/02/12
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/24No longer listed under review
国药集团容生制药有限公司
CYHS2501608
Fact date: 2026/10/24 · Site observation date: 2026/10/24
Accepted: 2025/04/29
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/20Marketing application approved
成都康泰源医药科技有限责任公司
CYHS2501821 · 国药准字H20266291
Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 66 ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Bumetanide Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy